First Cancer Medicine Decision Following Pharmac Funding Boost | Scoop News
Pharmac widens access to pembrolizumab (Keytruda) for advanced triple-negative breast cancer, head and neck cancer, colorectal cancer, bladder cancer, and Hodgkin lymphoma, and nivolumab (Opdivo) for kidney cancer. These decisions follow additional government funding in June. 1,000 people will access these treatments in the first year, increasing to 4,500 over five years.
Reference News
First Cancer Medicine Decision Following Pharmac Funding Boost | Scoop News
Pharmac widens access to pembrolizumab (Keytruda) for advanced triple-negative breast cancer, head and neck cancer, colorectal cancer, bladder cancer, and Hodgkin lymphoma, and nivolumab (Opdivo) for kidney cancer. These decisions follow additional government funding in June. 1,000 people will access these treatments in the first year, increasing to 4,500 over five years.